- Sorrento Therapeutics Inc (NASDAQ:SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured long-term follow-up data.
- Abivertinib selectively inhibits EGFR-activating and resistant mutation with nearly 300-fold greater potency than wild-type EGFR.
- In these Independent Review Committee (IRC)-assessed preliminary data, Abivertinib showed significant treatment benefits in 209 response evaluable, heavily treated NSCLC patients with an ORR of 56.5%.
- Related: Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer.
- A significant CR rate was seen with Abivertinib (5.3%) compared to AstraZeneca Plc’s (NASDAQ:AZN) Tagrisso (osimertinib) (0.5%), while the ORR rate is comparable between the two drugs.
- Overall survival was 28.2 months (versus Tagrisso’s median OS of 26.8 months).
- Sorrento is preparing the pre-FDA marketing application materials and package.
- Price Action: SRNE shares are up 5.51% at $1.87 on the last check Tuesday.
Yamana And Pan American Shareholders Approve Proposed Transaction Of All Of The Issued And Outstanding Common Shares Of The Company Following The Sale By Yamana Of Its Canadian Assets
Yamana Gold Inc. (TSX:YRI, NYSE:AUY, LSE:AUY)))) ("Yamana" or the "Company") is pleased to announce that at a special meeting of shareholders held earlier today ("the Meeting"), Yamana
